Advanced Stage Prostate Cancer Diagnoses On The Rise, CDC Reports

Federal researchers warn they have seen an increasing number of advanced stage prostate cancer cases diagnosed over the past two decades, even while overall prostate cancer rates have declined in the United States.

According to findings published earlier this month in the U.S. Centers of Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, prostate cancer cases seem to be getting diagnosed at later stages due to a lack of early screening, decreasing men’s risk of survival.

CDC researchers analyzed data on incidence and survival of prostate cancer in the U.S. using population-based cancer registries that contribute to U.S. Cancer Statistics. There were 3.1 million new cases of prostate cancer recorded from 2003 to 2017.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

During that same time period, the number of prostate cancer cases in the late stage increased from 4% in 2003 to 8% in 2017. However, the five year survival for late stage prostate cancer also improved during that time. From 2000 to 2005 survival rates were 29%. By 2011 to 2016, roughly 32% of late stage patients had positive five-year survival outlooks.

Five year survival rates were highest among Asian/Pacific Islanders at 42%, with Hispanics at 37% five year survival rates, American Indian/Alaska Natives at 32%, Black men at 31%, and White men at 29%.

Understanding diagnosis rates and survival rates among different patients may help doctors guide testing and treatment, the CDC noted.

Researchers said the spike in advanced stage cancers was somewhat inevitable given that in 2012 the U.S. Preventive Services Task Force recommended against the use of routine prostate cancer screenings, specifically the prostate-specific antigen (PSA) test. This led to more men not being screened until they had much later stages of cancer.

The screening recommendations were not reversed until 2018. This means the increase in late stage prostate cancer diagnoses will continue to increase for a time.

Men should undergo screening early, including the PSA test, according to the current recommendations. Then if screening leads to questionable results, the patient should discuss their options or further diagnostic testing with their doctor to prevent late stage diagnosis.

Among men in the U.S., prostate cancer is the second leading cause of cancer-related death. There are more than 3 million cases of prostate cancer in the U.S. every year. Prostate cancer is largely treatable during the early stages, but once it spreads it is most often lethal, making early diagnosis the key to improved treatment and survival.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.